Promoters Samina, Rumana Hamied exit Cipla by selling 1.72 percent stake

Published On 2024-12-03 10:24 GMT   |   Update On 2024-12-03 10:24 GMT
Advertisement

New Delhi: Samina Hamied and Rumana Hamied, promoters of the Indian pharmaceutical giant Cipla, have sold their 1.72 percent stake in the company for Rs 2,111 crore through open market transactions.

According to block deal data available on the National Stock Exchange (NSE), Samina Hamied sold 89.54 lakh shares of Cipla, amounting to 1.11 percent stake, while Rumana Hamied offloaded 49.43 lakh shares, representing 0.61 percent stake. The transactions mark their exit from the company.

Advertisement
The shares were disposed of at an average price of Rs 1,518.75 apiece, taking the combined transaction value to Rs 2,110.76 crore, PTI reported.
After the stake sale, the combined promoter and promoter group holding in Cipla has come down to 29.2 per cent from 30.92 per cent.

Singapore government, Societe Generale, Abu Dhabi Investment Authority, BNP Paribas, BofA Securities, Citigroup, Morgan Stanley, Goldman Sachs, Norges Bank, UBS, and Copthall Mauritius bought stakes in Cipla.

DSP Mutual Fund (MF), Axis MF, Aditya Birla Sun Life MF, ICICI Prudential MF, Motilal Oswal MF, SBI Life Insurance, and Tata AIA Life Insurance have also bought shares in Cipla.
Samina and Rumana, are nieces of Y K Hamied -- the non-executive chairman of Cipla.
In October, Cipla reported a 17 per cent increase in consolidated net profit to Rs 1,303 crore for the September quarter, driven by robust sales across markets.
The company had reported a net profit of Rs 1,115 crore in the July-September period of the last fiscal.
In May this year, Shirin Hamied, Rumana Hamied, Samina Hamied, and Okasa Pharma Pvt Ltd sold 2.53 per cent equity stake in Cipla for Rs 2,750 crore.
Cipla was founded by Khwaja Abdul Hamied in 1935

Read also: Cipla, Alkem vie for Rs 4,000 crore stake in India's largest stent manufacturer: Report

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News